Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

The impact of intestinal transplantation on quality of life.

Ambrose T, Holdaway L, Smith A, Howe H, Vokes L, Vrakas G, Reddy S, Giele H, Travis SPL, Friend PJ, Allan PJ.

Clin Nutr. 2019 Aug 31. pii: S0261-5614(19)33035-3. doi: 10.1016/j.clnu.2019.08.023. [Epub ahead of print]

PMID:
31522787
2.

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.

Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR.

Gut. 2019 Jul 8. pii: gutjnl-2019-318256. doi: 10.1136/gutjnl-2019-318256. [Epub ahead of print]

3.

Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative Colitis.

Vleugels JLA, Rutter MD, Ragunath K, Rees CJ, Ponsioen CY, Lahiff C, Ket SN, Wanders LK, Samuel S, Butt F, Kuiper T, Travis SPL, D'Haens G, Wang LM, van Eeden S, East JE, Dekker E.

J Crohns Colitis. 2019 May 24. pii: jjz074. doi: 10.1093/ecco-jcc/jjz074. [Epub ahead of print] No abstract available.

PMID:
31125049
4.

Authors' reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin and Quality of Life.

Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM.

Inflamm Bowel Dis. 2019 May 4;25(6):e62-e63. doi: 10.1093/ibd/izy338. No abstract available.

PMID:
30380064
5.

IBD2020 global forum: results of an international patient survey on quality of care.

Irving P, Burisch J, Driscoll R, Olsson M, Fullarton JR, Rodgers-Gray BS, Travis SP.

Intest Res. 2018 Oct;16(4):537-545. doi: 10.5217/ir.2018.00041. Epub 2018 Oct 10.

6.

Polyp-adjacent biopsies no longer required in inflammatory bowel disease.

Lahiff C, Wang LM, Travis SPL, East JE.

Gastrointest Endosc. 2018 Oct;88(4):782-783. doi: 10.1016/j.gie.2018.05.005. No abstract available.

PMID:
30217249
7.

Visceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life.

Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM.

Inflamm Bowel Dis. 2019 Feb 21;25(3):592-600. doi: 10.1093/ibd/izy278.

PMID:
30215805
8.

Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative Colitis.

Vleugels JLA, Rutter MD, Ragunath K, Rees CJ, Ponsioen CY, Lahiff C, Ket SN, Wanders LK, Samuel S, Butt F, Kuiper T, Travis SPL, D'Haens G, Wang LM, van Eeden S, East JE, Dekker E.

J Crohns Colitis. 2018 Nov 28;12(12):1438-1447. doi: 10.1093/ecco-jcc/jjy129.

PMID:
30202856
9.

Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia.

Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman SN, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM.

Nutrients. 2018 Sep 1;10(9). pii: E1192. doi: 10.3390/nu10091192.

10.

Analysis of the Gut Microbiome of Rural and Urban Healthy Indians Living in Sea Level and High Altitude Areas.

Das B, Ghosh TS, Kedia S, Rampal R, Saxena S, Bag S, Mitra R, Dayal M, Mehta O, Surendranath A, Travis SPL, Tripathi P, Nair GB, Ahuja V.

Sci Rep. 2018 Jul 4;8(1):10104. doi: 10.1038/s41598-018-28550-3.

11.

Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease.

Kedia S, Jain S, Goyal S, Bopanna S, Yadav DP, Sachdev V, Sahni P, Pal S, Dash NR, Makharia G, Travis SPL, Ahuja V.

Dig Dis Sci. 2018 Oct;63(10):2747-2753. doi: 10.1007/s10620-018-5157-6. Epub 2018 Jun 8.

PMID:
29948556
12.

Consequences of Identifying XIAP Deficiency in an Adult Patient With Inflammatory Bowel Disease.

Quaranta M, Wilson R, Gonçalves Serra E, Pandey S, Schwerd T, Gilmour K, Klenerman P, Powrie F, Keshav S, Travis SPL, Anderson CA, Uhlig HH.

Gastroenterology. 2018 Jul;155(1):231-234. doi: 10.1053/j.gastro.2018.03.069. Epub 2018 Jun 9. No abstract available.

PMID:
29894681
13.

Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices.

Irani NR, Wang LM, Collins GS, Keshav S, Travis SPL.

J Crohns Colitis. 2018 Nov 9;12(10):1151-1157. doi: 10.1093/ecco-jcc/jjy081.

PMID:
29893824
14.

Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.

Feagan BG, Bhayat F, Khalid M, Blake A, Travis SPL.

J Crohns Colitis. 2018 Jul 30;12(8):905-919. doi: 10.1093/ecco-jcc/jjy047.

15.

Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes from the European Society for Blood and Marrow Transplantation.

Brierley CK, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J, Onida F, Cassinotti A, Satsangi J, Kazmi M, López-Sanromán A, Schmidt C, Farge D, Travis SPL, Hawkey CJ, Snowden JA; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP).

J Crohns Colitis. 2018 May 18. doi: 10.1093/ecco-jcc/jjy069. [Epub ahead of print]

16.

Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?

Fairhurst NG, Travis SPL.

Intest Res. 2018 Apr;16(2):209-215. doi: 10.5217/ir.2018.16.2.209. Epub 2018 Apr 30. Review.

17.

Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial.

Vleugels JLA, Rutter MD, Ragunath K, Rees CJ, Ponsioen CY, Lahiff C, Ket SN, Wanders LK, Samuel S, Butt F, Kuiper T, Travis SPL, D'Haens G, Wang LM, van Eeden S, East JE, Dekker E.

Lancet Gastroenterol Hepatol. 2018 May;3(5):305-316. doi: 10.1016/S2468-1253(18)30055-4. Epub 2018 Mar 20.

PMID:
29567006
18.

Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study.

Jain S, Kedia S, Bopanna S, Yadav DP, Goyal S, Sahni P, Pal S, Dash NR, Makharia G, Travis SPL, Ahuja V.

Intest Res. 2018 Jan;16(1):69-74. doi: 10.5217/ir.2018.16.1.69. Epub 2018 Jan 18.

19.

Diagnostic Yield of Dysplasia in Polyp-adjacent Biopsies for Patients with Inflammatory Bowel Disease: A Cross-sectional Study.

Lahiff C, Mun Wang L, Travis SPL, East JE.

J Crohns Colitis. 2018 May 25;12(6):670-676. doi: 10.1093/ecco-jcc/jjy007.

PMID:
29385427
20.

Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus.

Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, Derieppe M, Dignass A, Driscoll R, Fitzpatrick R, Gaarentstroom-Lunt J, Higgins PD, Kotze PG, Meissner J, O'Connor M, Ran ZH, Siegel CA, Terry H, van Deen WK, van der Woude CJ, Weaver A, Yang SK, Sands BE, Vermeire S, Travis SP.

J Crohns Colitis. 2018 Mar 28;12(4):408-418. doi: 10.1093/ecco-jcc/jjx161.

PMID:
29216349
21.

NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease.

Schwerd T, Bryant RV, Pandey S, Capitani M, Meran L, Cazier JB, Jung J, Mondal K, Parkes M, Mathew CG, Fiedler K, McCarthy DJ; WGS500 Consortium; Oxford IBD cohort study investigators; COLORS in IBD group investigators; UK IBD Genetics Consortium, Sullivan PB, Rodrigues A, Travis SPL, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J; INTERVAL Study, Russell RK, Wilson DC, Kelsen JR, Cornall R, Denson LA, Kugathasan S, Knaus UG, Serra EG, Anderson CA, Duerr RH, McGovern DP, Cho J, Powrie F, Li VS, Muise AM, Uhlig HH.

Mucosal Immunol. 2018 Mar;11(2):562-574. doi: 10.1038/mi.2017.74. Epub 2017 Nov 1.

22.

Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study.

Jain S, Kedia S, Bopanna S, Sachdev V, Sahni P, Dash NR, Pal S, Vishnubhatla S, Makharia G, Travis SPL, Ahuja V.

J Crohns Colitis. 2017 Oct 27;11(11):1309-1316. doi: 10.1093/ecco-jcc/jjx084.

PMID:
29088461
23.

Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice.

Bryant RV, Costello SP, Schoeman S, Sathananthan D, Knight E, Lau SY, Schoeman MN, Mountifield R, Tee D, Travis SPL, Andrews JM.

J Gastroenterol Hepatol. 2018 Mar;33(3):599-607. doi: 10.1111/jgh.13923.

PMID:
28806471
24.

Predictors of long-term outcomes in patients with acute severe colitis: A northern Indian cohort study.

Jain S, Kedia S, Sethi T, Bopanna S, Yadav DP, Goyal S, Padhan R, Venigalla PM, Sahni P, Dash NR, Pal S, Makharia G, Travis SPL, Ahuja V.

J Gastroenterol Hepatol. 2018 Mar;33(3):615-622. doi: 10.1111/jgh.13921.

PMID:
28801987
25.

Editorial: gut selective immunosuppression-is it a double edged sword? Authors' reply.

Bye WA, Jairath V, Travis SPL.

Aliment Pharmacol Ther. 2017 Aug;46(3):374. doi: 10.1111/apt.14166. No abstract available.

26.

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators, Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788d. No abstract available.

PMID:
28586341
27.

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.

Bye WA, Jairath V, Travis SPL.

Aliment Pharmacol Ther. 2017 Jul;46(1):3-15. doi: 10.1111/apt.14075. Epub 2017 Apr 27. Review.

28.

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators, Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 May;23(5):579-589. doi: 10.1038/nm.4307. Epub 2017 Apr 3. Erratum in: Nat Med. 2017 Jun 6;23 (6):788.

29.

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.

Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P.

Aliment Pharmacol Ther. 2017 Mar;45(6):801-813. doi: 10.1111/apt.13948. Epub 2017 Jan 23. Review.

30.

Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis.

Guirgis M, Wendt E, Wang LM, Walsh A, Burger D, Bryant RV, Kent A, Adamson R, Brain O, Travis SPL, Keshav S.

J Crohns Colitis. 2017 Apr 1;11(4):460-467. doi: 10.1093/ecco-jcc/jjw174.

PMID:
27856523
31.

The role of a defunctioning stoma for colonic and perianal Crohn's disease in the biological era.

Martí-Gallostra M, Myrelid P, Mortensen N, Keshav S, Travis SP, George B.

Scand J Gastroenterol. 2017 Mar;52(3):251-256. doi: 10.1080/00365521.2016.1205127. Epub 2016 Nov 18.

32.

Predicting the Individual Risk of Acute Severe Colitis at Diagnosis.

Cesarini M, Collins GS, Rönnblom A, Santos A, Wang LM, Sjöberg D, Parkes M, Keshav S, Travis SP.

J Crohns Colitis. 2017 Mar 1;11(3):335-341. doi: 10.1093/ecco-jcc/jjw159.

33.

Central Endoscopy Reading in Inflammatory Bowel Diseases.

Panés J, Feagan BG, Hussain F, Levesque BG, Travis SP.

J Crohns Colitis. 2016 Sep;10 Suppl 2:S542-7. doi: 10.1093/ecco-jcc/jjv171. Review.

PMID:
27604978
34.

Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.

Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, Gordon JN, Hawthorne AB, Hilton M, Hutchings HA, Jawhari AU, Longo M, Mansfield J, Morgan JM, Rapport F, Seagrove AC, Sebastian S, Shaw I, Travis SP, Watkins A.

Lancet Gastroenterol Hepatol. 2016 Sep;1(1):15-24.

35.

Current best practice for disease activity assessment in IBD.

Walsh AJ, Bryant RV, Travis SP.

Nat Rev Gastroenterol Hepatol. 2016 Oct;13(10):567-79. doi: 10.1038/nrgastro.2016.128. Epub 2016 Sep 1. Review.

PMID:
27580684
36.

Causality and Chance in the Development of Cancer.

East JE, Travis SP, Leedham SJ.

N Engl J Med. 2015 Oct 15;373(16):1578-9. doi: 10.1056/NEJMc1509651. No abstract available.

PMID:
26466006
37.

'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?

Atkinson NS, Reynolds DJ, Travis SP.

Intest Res. 2015 Jul;13(3):227-32. doi: 10.5217/ir.2015.13.3.227. Epub 2015 Jun 9. Review.

38.

Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.

Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP.

Gut. 2016 Mar;65(3):408-14. doi: 10.1136/gutjnl-2015-309598. Epub 2015 May 18.

PMID:
25986946
39.

Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial.

Jairath V, Kahan BC, Gray A, Doré CJ, Mora A, James MW, Stanley AJ, Everett SM, Bailey AA, Dallal H, Greenaway J, Le Jeune I, Darwent M, Church N, Reckless I, Hodge R, Dyer C, Meredith S, Llewelyn C, Palmer KR, Logan RF, Travis SP, Walsh TS, Murphy MF.

Lancet. 2015 Jul 11;386(9989):137-44. doi: 10.1016/S0140-6736(14)61999-1. Epub 2015 May 5.

PMID:
25956718
40.

The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].

Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA, Sandborn WJ.

J Crohns Colitis. 2015 Aug;9(8):607-16. doi: 10.1093/ecco-jcc/jjv077. Epub 2015 May 8.

41.

Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial.

Campbell HE, Stokes EA, Bargo D, Logan RF, Mora A, Hodge R, Gray A, James MW, Stanley AJ, Everett SM, Bailey AA, Dallal H, Greenaway J, Dyer C, Llewelyn C, Walsh TS, Travis SP, Murphy MF, Jairath V; TRIGGER investigators.

BMJ Open. 2015 Apr 29;5(4):e007230. doi: 10.1136/bmjopen-2014-007230.

42.

Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative.

Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, Peyrin-Biroulet L, Colombel JF.

J Crohns Colitis. 2015 Aug;9(8):601-6. doi: 10.1093/ecco-jcc/jjv067. Epub 2015 Apr 23.

PMID:
25908718
43.

Response to Villanacci et. al.

Bryant RV, Winer S, Travis SP, Riddell RH.

J Crohns Colitis. 2015 May;9(5):429. doi: 10.1093/ecco-jcc/jjv046. Epub 2015 Mar 11. No abstract available.

PMID:
25761770
44.

Introducing vedolizumab to clinical practice: who, when, and how?

Bryant RV, Sandborn WJ, Travis SP.

J Crohns Colitis. 2015 Apr;9(4):356-66. doi: 10.1093/ecco-jcc/jjv033. Epub 2015 Feb 16. Review.

PMID:
25687206
45.

Conventional drug therapy for inflammatory bowel disease.

Bryant RV, Brain O, Travis SP.

Scand J Gastroenterol. 2015 Jan;50(1):90-112. doi: 10.3109/00365521.2014.968864. Review.

PMID:
25523560
46.

Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative.

Bryant RV, Winer S, Travis SP, Riddell RH.

J Crohns Colitis. 2014 Dec;8(12):1582-97. doi: 10.1016/j.crohns.2014.08.011. Epub 2014 Sep 27. Review.

47.

Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis.

Ford AC, Luthra P, Hanauer SB, Travis SP, Harris MS, Reinisch W.

Clin Gastroenterol Hepatol. 2014 Dec;12(12):1981-90. doi: 10.1016/j.cgh.2014.08.038. Epub 2014 Sep 15. Review.

48.

Poor outcomes in hospitalized patients with gastrointestinal bleeding: impact of baseline risk, bleeding severity, and process of care.

Jairath V, Thompson J, Kahan BC, Daniel R, Hearnshaw SA, Travis SP, Murphy MF, Palmer KR, Logan RF.

Am J Gastroenterol. 2014 Oct;109(10):1603-12. doi: 10.1038/ajg.2014.263. Epub 2014 Aug 26.

PMID:
25155225
49.

The diagnostic approach to monogenic very early onset inflammatory bowel disease.

Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, Ouahed J, Wilson DC, Travis SP, Turner D, Klein C, Snapper SB, Muise AM; COLORS in IBD Study Group and NEOPICS.

Gastroenterology. 2014 Nov;147(5):990-1007.e3. doi: 10.1053/j.gastro.2014.07.023. Epub 2014 Jul 21. Review.

50.

Healing under pressure: hyperbaric oxygen and myocutaneous flap repair for extreme persistent perineal sinus after proctectomy for inflammatory bowel disease.

Chan XH, Koh CE, Glover M, Bryson P, Travis SP, Mortensen NJ.

Colorectal Dis. 2014 Mar;16(3):186-90. doi: 10.1111/codi.12500.

PMID:
24267200

Supplemental Content

Loading ...
Support Center